DYN Q1 2023 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$45M

Net Income

-$44M

EPS (Diluted)

$-0.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$289M

Total Liabilities

$47M

Stockholders' Equity

$242M

Cash & Equivalents

$181M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$45M	-$36M	-27.1%
Net Income	-$44M	-$36M	-24.2%